Skip to main content
. 2018 Aug 2;51(5):e12480. doi: 10.1111/cpr.12480

Figure 5.

Figure 5

ZLDI‐8 (3.13 μM) combined with 5‐FU or irinotecan reversed the epithelial‐mesenchymal transition. A, Migratory ability was detected by wound healing assays when cells were treated with ZLDI‐8 (3.13 μM), 5‐FU (2 μM)/irinotecan (8 μM), alone or combination. B, Bar graphs showed the quantitative results of the migration. C, Transwell assays was used to measure the invasive ability of ZLDI‐8 (3.13 μM), 5‐FU (2 μM)/irinotecan (8 μM), alone or combination. (magnification, ×40). D, Bar graphs showed the quantitative results of the invasion (right). (E) Western blot assay was used to evaluate the expression of EMT markers (E‐cadherin, Vimentin and Twist1). β‐actin was used as a loading control. *P < .05. **P < .01, ***P < .001. Irinotecan (irino)